Clinical Trial Update: NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.

View source ↗

Summary

A completed clinical trial update reports that the NMP22 biomarker test shows improved sensitivity for detecting bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Bladder Cancer | Status: COMPLETED